JP2007517049A - 再発性病状を治療するための組成物および方法 - Google Patents

再発性病状を治療するための組成物および方法 Download PDF

Info

Publication number
JP2007517049A
JP2007517049A JP2006547469A JP2006547469A JP2007517049A JP 2007517049 A JP2007517049 A JP 2007517049A JP 2006547469 A JP2006547469 A JP 2006547469A JP 2006547469 A JP2006547469 A JP 2006547469A JP 2007517049 A JP2007517049 A JP 2007517049A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
dcs
pharmacological substance
pharmacological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006547469A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007517049A5 (enExample
Inventor
マクデビット、ジェイソン
デイビス、マイケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2007517049A publication Critical patent/JP2007517049A/ja
Publication of JP2007517049A5 publication Critical patent/JP2007517049A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006547469A 2003-12-29 2004-12-29 再発性病状を治療するための組成物および方法 Pending JP2007517049A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53300303P 2003-12-29 2003-12-29
US62525304P 2004-11-05 2004-11-05
PCT/US2004/043628 WO2005065308A2 (en) 2003-12-29 2004-12-29 Compositions and methods to treat recurrent medical conditions

Publications (2)

Publication Number Publication Date
JP2007517049A true JP2007517049A (ja) 2007-06-28
JP2007517049A5 JP2007517049A5 (enExample) 2008-02-21

Family

ID=34752985

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006547469A Pending JP2007517049A (ja) 2003-12-29 2004-12-29 再発性病状を治療するための組成物および方法

Country Status (8)

Country Link
US (2) US7846913B2 (enExample)
EP (1) EP1703907A4 (enExample)
JP (1) JP2007517049A (enExample)
KR (1) KR20070007276A (enExample)
AU (1) AU2004311869A1 (enExample)
CA (1) CA2592631A1 (enExample)
RU (1) RU2006127475A (enExample)
WO (1) WO2005065308A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025173704A1 (ja) * 2024-02-16 2025-08-21 エフバイタル株式会社 薬剤のスクリーニング方法、および剤

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1383465B1 (en) * 2001-03-29 2011-08-10 Michael Davis Acute pharmacologic augmentation of psychotherapy with d-cycloserine
US20050209317A1 (en) * 2004-03-22 2005-09-22 Apkarian A V Method and compositions for treatment of chronic neuropathic pain
US20060084659A1 (en) * 2004-10-19 2006-04-20 Michael Davis Augmentation of psychotherapy with cannabinoid reuptake inhibitors
MX2007009915A (es) * 2005-02-15 2007-11-06 Elan Pharma Int Ltd Formulaciones en aerosol e inyectables de benzodiazepina nanoparticulada.
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
EP1906925A1 (en) * 2005-07-28 2008-04-09 Teikoku Pharma USA, Inc. Gelled donepezil compositions and methods for making and using the same
BRPI0615972A2 (pt) 2005-07-29 2011-05-31 Concert Pharmaceuticals Inc composto isolado, mistura, composição, item de manufatura, uso de um composto, método para determinar a concentração do composto em uma amostra biológica, kit de diagnóstico e método para avaliar a estabilidade metabólica de um composto
KR101140110B1 (ko) * 2006-07-07 2012-06-04 테바 파마슈티컬 인더스트리즈 리미티드 타달라필 및 하나 이상의 담체를 포함하는 고체 조성물
WO2008124814A2 (en) * 2007-04-10 2008-10-16 Mcdevitt Jason P Sublingual formulations of d-cycloserine and methods of using same
ATE515259T1 (de) * 2007-05-29 2011-07-15 Lek Pharmaceuticals Pharmazeutische zusammensetzung mit eszopiclon
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
US20100291225A1 (en) * 2008-01-14 2010-11-18 Jubilant Organosys Ltd. Stabilized Sustained Release Composition of Bupropion Hydrochloride and Process For Preparing the Same
US20100204291A1 (en) * 2009-02-12 2010-08-12 Mcdevitt Jason P Method for Facilitating Extinction Training Using D-Cycloserine
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
EP2670409B1 (en) * 2011-01-31 2018-04-18 Serotech, LLC Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder
US10583138B2 (en) 2012-07-12 2020-03-10 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
MX336979B (es) * 2011-12-16 2016-02-09 Senosiain S A De C V Lab Combinacion farmaceutica antineuritica y composiciones.
US9877951B2 (en) 2015-02-12 2018-01-30 College Of William And Mary Method for treating dementia
US20170143681A1 (en) 2015-11-02 2017-05-25 Apkarian Technologies Llc Methods and compositions for treating pain
US11291654B2 (en) * 2018-09-13 2022-04-05 Syneurx International (Taiwan) Corp. Formulations of cycloserine compounds and applications thereof
US10485790B1 (en) * 2018-09-13 2019-11-26 Syneurx International (Taiwan) Corp. Salts of cycloserine compounds and applications thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002543124A (ja) * 1999-04-29 2002-12-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 潜在的な抗精神病薬としてのグリシン開裂システム阻害剤
JP2003192614A (ja) * 2001-12-06 2003-07-09 Pfizer Inc 痛みを低減させるためのキット

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5061721A (en) 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
JPH03236315A (ja) * 1989-12-05 1991-10-22 Nippon Oil & Fats Co Ltd 抗精神病薬
US5260324A (en) 1990-02-06 1993-11-09 G. D. Searle & Company Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5086072A (en) 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
US5428069A (en) 1993-01-11 1995-06-27 The United States Of America As Represented By The Department Of Health & Human Services Treating cognition with, aminocyclopropanecarboxylic derivatives
US5523323A (en) 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
US6355681B2 (en) 1995-12-07 2002-03-12 Glytech, Inc. Glycine substitutes and precursors for treating a psychosis
US6133281A (en) * 1996-10-24 2000-10-17 Harbor-Ucla Research And Education Institute NMDA receptor blockers in the therapy of urogenital disease
WO1999051252A1 (en) * 1998-04-03 1999-10-14 The Daily Wellness Company Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation
DE69936848T2 (de) 1998-04-14 2008-05-15 The General Hospital Corp., Boston Verwendung von d-serin oder d-alanin zur behandlung von schizophrenie
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US20010053780A1 (en) * 1999-04-30 2001-12-20 Whitaker John S. Daily treatment for erectile dysfunction using a PDE5 inhibitor
US6333357B1 (en) 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
US20050096396A1 (en) 2002-03-28 2005-05-05 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
EP1383465B1 (en) 2001-03-29 2011-08-10 Michael Davis Acute pharmacologic augmentation of psychotherapy with d-cycloserine
EP1471909A4 (en) * 2002-01-16 2007-07-25 Endo Pharmaceuticals Inc PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002543124A (ja) * 1999-04-29 2002-12-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 潜在的な抗精神病薬としてのグリシン開裂システム阻害剤
JP2003192614A (ja) * 2001-12-06 2003-07-09 Pfizer Inc 痛みを低減させるためのキット

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025173704A1 (ja) * 2024-02-16 2025-08-21 エフバイタル株式会社 薬剤のスクリーニング方法、および剤

Also Published As

Publication number Publication date
EP1703907A2 (en) 2006-09-27
WO2005065308A3 (en) 2005-12-08
US20050143314A1 (en) 2005-06-30
AU2004311869A1 (en) 2005-07-21
US7846913B2 (en) 2010-12-07
US20110071102A1 (en) 2011-03-24
RU2006127475A (ru) 2008-02-10
US8309535B2 (en) 2012-11-13
EP1703907A4 (en) 2009-03-25
WO2005065308A2 (en) 2005-07-21
KR20070007276A (ko) 2007-01-15
CA2592631A1 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
US8309535B2 (en) Compositions and methods to treat recurrent medical conditions
JP6771512B2 (ja) 抗不安薬組成物、製剤および使用方法
JP5675650B2 (ja) 向精神薬の働きを向上させるソルビン酸、安息香酸及びその誘導体
JP5646126B2 (ja) 鎮静剤と神経伝達物質調節剤の併用、および睡眠の質の向上方法および鬱の治療方法
US20060122127A1 (en) Methods for reducing the side effects associated with mirtzapine treatment
US9700548B2 (en) Antihistamines combined with dietary supplements for improved health
US20060252761A1 (en) Augmentation of extinction via administration of sub-antimicrobial doses of D-cycloserine
JP6196041B2 (ja) 大うつ病を有する患者において減量療法を提供する方法
JP2009543767A (ja) フリバンセリンとカフェインとを含む組成物、その調製方法及び薬剤としての使用
KR20090019765A (ko) 타액 분비 과다증 치료를 위한 알파-2 수용체 작용제(클로니딘) 및 항-무스카린제(옥시부티닌)의 복합물
TW200524582A (en) Pharmaceutical composition comprising rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
AU748993B2 (en) Pharmaceutical combinations containing tramadol
CA2899602A1 (en) Pharmaceutical uses of inorganic nitrites
CN114555070B (zh) 月经周期诱发的症状治疗
US20110244057A1 (en) Combination therapies with topiramate for seizures, restless legs syndrome, and other neurological conditions
US20060084659A1 (en) Augmentation of psychotherapy with cannabinoid reuptake inhibitors
US20070219201A1 (en) Combination of atomoxetine and a 5ht1a receptor agonist for treating adhd and other disorders
KR20180074707A (ko) 저 용량 경구 디피리다몰 조성물 및 이의 용도
US20140148465A1 (en) Compositions and Methods to Improve Treatment of Medical Conditions Using D-Cycloserine
PL231163B1 (pl) Kombinacja i kompozycja farmaceutyczna do zastosowania w leczeniu i/lub zapobieganiu bólowi z powodu umiarkowanych do ciężkich neuralgii o różnorodnym umiejscowieniu
KR20030019444A (ko) 안지오텐신 ⅱ 길항물질의 신규한 용도
CN1972685A (zh) 治疗复发性的需要治疗的病症的组合物及方法
TW201946619A (zh) 治療神經性病變疼痛之方法
WO2009147831A1 (ja) 精神障害の治療方法および治療用医薬組成物
US20130267533A1 (en) 5ht1a agonists for treatment of high cholesterol

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071229

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071229

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101026

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110412